# Changes of serum MMP-9, NSE, MPO levels and prognostic influencing factors in patients with intracranial aneurysm undergoing interventional embolization at different treatment timing

**Authors:** Chunmiao Wu, Xingyu Dong, Qiang Li, Shengming Liu, Yuhao He, Yang Zhang, Sunfu Zhang

PMC · DOI: 10.5937/jomb0-44364 · 2024-01-25

## TL;DR

This study examines how timing of treatment affects biomarker levels and outcomes in patients with brain aneurysms undergoing embolization.

## Contribution

The study identifies timing-related changes in MMP-9, NSE, and MPO levels and their impact on prognosis in intracranial aneurysm patients.

## Key findings

- Early treatment (≤72 h) was associated with better outcomes compared to delayed treatment (>72 h).
- Serum levels of MMP-9, NSE, and MPO were significantly altered post-surgery.
- Univariate and multivariate analyses identified key prognostic factors influencing patient recovery.

## Abstract

To analyzes the changes in serum levels of matrix metalloproteinase-9 (MMP-9), neuroenolase (NSE), myeloperoxidase (MPO) and prognostic factors in patients with intracranial aneurysm (IA) undergoing interventional embolization at different treatment times.

A retrospective analysis was made of 200 IA patients admitted to our department from January 2018 to June 2021 was performed. All patients underwent interventional embolization. According to the timing of surgery, the patients were divided into an early group (n=120, onset to surgery ≤72 h) and a delayed group (n=80, onset to surgery >72 h). The effect of embolization, complications and neurological deficit scale (NDS) scores were compared between the two groups. Serum MMP-9, NSE and MPO levels were compared before and after surgery, and the prognosis of all patients within 2 years after surgery was assessed by the Glasgow outcome scale (GOS) and divided accordingly into the good prognosis group (n=147) and the poor prognosis group (n=53) accordingly, and the prognostic factors influencing the patients were analyzed univariately and multifactorially.

## Linked entities

- **Proteins:** MMP9 (matrix metallopeptidase 9), ENO2 (enolase 2), MPO (myeloperoxidase)

## Full-text entities

- **Genes:** MPO (myeloperoxidase) [NCBI Gene 4353], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}
- **Diseases:** neurological deficit (MESH:D009461), Glasgow (MESH:C536506), embolization (MESH:D004617), IA (MESH:D002532)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10943457/full.md

---
Source: https://tomesphere.com/paper/PMC10943457